Robert W. Baird Has Lowered Expectations for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) had its price objective reduced by analysts at Robert W. Baird from $30.00 to $29.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's target price points to a potential upside of 101.53% from the company's current price.

A number of other research analysts have also commented on DNLI. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target on the stock. Wedbush lowered their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday. The Goldman Sachs Group reduced their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Cantor Fitzgerald upgraded Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $33.79.

Denali Therapeutics Trading Down 0.3 %

NASDAQ:DNLI traded down $0.04 during mid-day trading on Thursday, hitting $14.39. The stock had a trading volume of 1,367,985 shares, compared to its average volume of 1,092,248. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $33.33. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -5.21 and a beta of 1.49. The company has a 50 day simple moving average of $14.27 and a 200-day simple moving average of $19.99.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same quarter in the prior year, the company earned ($0.68) earnings per share. As a group, equities research analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DNLI. Vanguard Group Inc. lifted its position in shares of Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after acquiring an additional 843,996 shares in the last quarter. FMR LLC lifted its holdings in shares of Denali Therapeutics by 2.4% in the fourth quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after purchasing an additional 188,368 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Denali Therapeutics by 8.8% in the fourth quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock worth $67,573,000 after buying an additional 268,378 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Denali Therapeutics by 6.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company's stock worth $62,335,000 after buying an additional 188,820 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Denali Therapeutics by 19.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock valued at $37,805,000 after buying an additional 295,594 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.